Rayson, D.; Bertin, J.; Lemelin, M.; Tong, M.; Ng, R.; Ding, P.; Cheung, W.Y.; Sharma, A.; On, P.V.; Feugère, G.;
et al. Real-World Utilization of Palbociclib as First-Line Treatment for Canadian HR+/HER2− Women with Metastatic Breast Cancer: Results from PALCAN Study. Curr. Oncol. 2026, 33, 81.
https://doi.org/10.3390/curroncol33020081
AMA Style
Rayson D, Bertin J, Lemelin M, Tong M, Ng R, Ding P, Cheung WY, Sharma A, On PV, Feugère G,
et al. Real-World Utilization of Palbociclib as First-Line Treatment for Canadian HR+/HER2− Women with Metastatic Breast Cancer: Results from PALCAN Study. Current Oncology. 2026; 33(2):81.
https://doi.org/10.3390/curroncol33020081
Chicago/Turabian Style
Rayson, Daniel, Jonathan Bertin, Maxim Lemelin, Madeline Tong, Ryan Ng, Philip Ding, Winson Y. Cheung, Arushi Sharma, Phu Vinh On, Guillaume Feugère,
and et al. 2026. "Real-World Utilization of Palbociclib as First-Line Treatment for Canadian HR+/HER2− Women with Metastatic Breast Cancer: Results from PALCAN Study" Current Oncology 33, no. 2: 81.
https://doi.org/10.3390/curroncol33020081
APA Style
Rayson, D., Bertin, J., Lemelin, M., Tong, M., Ng, R., Ding, P., Cheung, W. Y., Sharma, A., On, P. V., Feugère, G., & Lupichuk, S.
(2026). Real-World Utilization of Palbociclib as First-Line Treatment for Canadian HR+/HER2− Women with Metastatic Breast Cancer: Results from PALCAN Study. Current Oncology, 33(2), 81.
https://doi.org/10.3390/curroncol33020081
